Skip navigation

Repositorio Institucional Continental


Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12394/7542
Title: Efficacy and safety of oncoplastic surgery plus drug therapy for chronic tuberculous granulomatous mastitis
Authors: Paz, M.E.P.
Lazo, L.B.
Palao, D.C.
Pinto Ruiz, D.F.
Huaman, M.R.
Quispe, A.M.
Keywords: Tuberculosis
Enfermedades bacterianas
Publisher: Universidad Continental
Issue Date: 1-Jun-2020
Date available: 1-Jul-2020
Creation date: 2020
Bibliographic citation: Paz, M.E.P., Lazo, L.B., Palao, D.C., Pinto Ruiz, D.F., Huaman, M.R., Quispe, A.M. (2020). Efficacy and safety of oncoplastic surgery plus drug therapy for chronic tuberculous granulomatous mastitis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 24 (6), 585-590. https://doi.org/10.5588/ijtld.19.0478
DOI: https://doi.org/10.5588/ijtld.19.0478
Abstract: BACKGROUND: Chronic tuberculous granulomatous mastitis (CTGM) is a rare form of tuberculosis (TB) treated primarily with anti-TB drugs. Oncoplastic surgery (OS) has been proposed as adjuvant therapy for CTGM. METHOD: We followed for 1 year every CTGM patients and assessed the efficacy (defined as non-recurrence and no need for corticosteroids) and safety attributable to the standard anti-TB drugs therapy with and without OS. RESULTS: We analysed 128 CTGM cases, including 78 (61%) treated with OS plus anti-TB drugs and 50 (39%) with anti-TB drugs only. We observed a significantly higher efficacy among those exposed vs. unexposed to OS (100% vs. 92%; prevalence ratio [PR] 1.09, 95% CI 1.00–1.18), with no difference in the number of complications (21% vs. 8%; PR 2.56, 95% CI 0.91–7.26). We also observed that the incidence of post-operative complications decreased by 50% when OS was postponed from after Month 1 to after completing Month 2 of anti-TB drugs treatment (19% to 8%; PR 0.46, 95% CI 0.13–1.62). CONCLUSION: OS appears to represent an efficacious and safe adjuvant therapy when combined with anti-TB drugs in the treatment of CTGM patients, but clinical trials are needed to prove this observation.
Notes: El texto completo de este trabajo no está disponible en el Repositorio Institucional - Continental por restricciones de la casa editorial donde ha sido publicado.
Included in: https://www.ingentaconnect.com/content/iuatld/ijtld/2020/00000024/00000006/art00008;jsessionid=1kiehl9of0r90.x-ic-live-01#Refs
metadata.dc.format.extent: p. 585-590
Access: Restringido
Source: Universidad Continental
Repositorio Institucional - Continental
Appears in Collections:Artículos Científicos

Files in This Item:
There are no files associated with this item.
Show full item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.